- Home
- MDGL vs SUM Comparison
MDGL vs SUM Comparison
Compare MDGL & SUM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- SUM
- Stock Information
- Founded
- MDGL 2011
- SUM 2009
- Country
- MDGL United States
- SUM United States
- Employees
- MDGL N/A
- SUM N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- SUM Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- MDGL Health Care
- SUM Industrials
- Exchange
- MDGL Nasdaq
- SUM Nasdaq
- Market Cap
- MDGL 7.4B
- SUM 8.8B
- IPO Year
- MDGL N/A
- SUM 2015
- Fundamental
- Price
- MDGL $308.44
- SUM $50.55
- Analyst Decision
- MDGL Buy
- SUM Buy
- Analyst Count
- MDGL 14
- SUM 15
- Target Price
- MDGL $347.33
- SUM $50.62
- AVG Volume (30 Days)
- MDGL 355.8K
- SUM 5.7M
- Earning Date
- MDGL 10-31-2024
- SUM 02-12-2025
- Dividend Yield
- MDGL N/A
- SUM N/A
- EPS Growth
- MDGL N/A
- SUM N/A
- EPS
- MDGL N/A
- SUM 0.92
- Revenue
- MDGL $76,813,000.00
- SUM $3,754,547,000.00
- Revenue This Year
- MDGL N/A
- SUM $58.70
- Revenue Next Year
- MDGL $194.49
- SUM $6.28
- P/E Ratio
- MDGL N/A
- SUM $55.07
- Revenue Growth
- MDGL N/A
- SUM 49.49
- 52 Week Low
- MDGL $168.25
- SUM $34.38
- 52 Week High
- MDGL $368.29
- SUM $53.49
- Technical
- Relative Strength Index (RSI)
- MDGL 51.11
- SUM 60.21
- Support Level
- MDGL $289.80
- SUM $50.30
- Resistance Level
- MDGL $315.09
- SUM $50.87
- Average True Range (ATR)
- MDGL 12.44
- SUM 0.22
- MACD
- MDGL -4.11
- SUM -0.31
- Stochastic Oscillator
- MDGL 48.58
- SUM 33.22
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About SUM Summit Materials Inc.
Summit Materials Inc is engaged in the production and sale of aggregates, cement, ready-mix concrete, asphalt paving mix and concrete products and owns and operates quarries, sand and gravel pits, two cement plants, cement distribution terminals, ready-mix concrete plants, asphalt plants and landfill sites. It is also engaged in paving and related services. The Company's three operating and reporting segments are the West, East and Cement segments. It operates in 21 U.S. states and in British Columbia, Canada and has assets in 21 U.S. states and in British Columbia, Canada through its platform.